DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for qRT-PCR/ NP expression/Immunofluorescence are 13

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_7546	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2	Wuhan/WIV04/2022	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (50 %)	Approved	32438446
DrugRepV_7547	Chloroquine	Antiparasitic products, Insectisides and Repellents	Malaria	SARS Coronavirus-2	Wuhan/WIV04/2022	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (90 %)	Approved	32438446
DrugRepV_7548	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	Wuhan/WIV04/2022	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (50 %)	Experimental	32438446
DrugRepV_7549	Remdesivir	Antiviral	Hepatitis C | Ebola	SARS Coronavirus-2	Wuhan/WIV04/2022	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (90 %)	Experimental	32438446
DrugRepV_7552	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	SARS Coronavirus-2	Wuhan/WIV04/2020	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (50 %)	Approved, Investigational, Vet approved	32438446
DrugRepV_7553	Nitazoxanide	Antiparasitic products, Insectisides and Repellents	Diarrhea	SARS Coronavirus-2	Wuhan/WIV04/2020	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (90 %)	Approved, Investigational, Vet approved	32438446
DrugRepV_7613	Toremifene	Antineoplastic and Immunomodulating Agents	Breast Cancer	SARS Coronavirus-2	Wuhan/WIV04/2023	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (50 %)	Approved, Investigational	32438446
DrugRepV_7649	Favipiravir	Antiviral	Influenza virus	SARS Coronavirus-2	Wuhan/WIV04/2019	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (50 %)	Investigational	32438446
DrugRepV_7650	Favipiravir	Antiviral	Influenza virus	SARS Coronavirus-2	Wuhan/WIV04/2019	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (90 %)	Investigational	32438446
DrugRepV_7655	Penciclovir	Antiinfectives For Systemic Use	Recurrent cold sores on the lips and face from Herpesvirus invections	SARS Coronavirus-2	Wuhan/WIV04/2019	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (50 %)	Approved	32438446
DrugRepV_7656	Penciclovir	Antiinfectives For Systemic Use	Recurrent cold sores on the lips and face from Herpesvirus invections	SARS Coronavirus-2	Wuhan/WIV04/2019	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (90 %)	Approved	32438446
DrugRepV_7659	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	SARS Coronavirus-2	Wuhan/WIV04/2022	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (50 %)	Approved	32438446
DrugRepV_7660	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	SARS Coronavirus-2	Wuhan/WIV04/2022	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (90 %)	Approved	32438446